• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纵向项目反应理论模型在帕金森病进展建模中的应用。

Application of longitudinal item response theory models to modeling Parkinson's disease progression.

机构信息

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Critical Path Institute, Tucson, Arizona, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1382-1392. doi: 10.1002/psp4.12853. Epub 2022 Aug 9.

DOI:10.1002/psp4.12853
PMID:35895005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9574723/
Abstract

The Movement Disorder Society revised version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts 2 and 3 reflect patient-reported functional impact and clinician-reported severity of motor signs of Parkinson's disease (PD), respectively. Total scores are common clinical outcomes but may obscure important time-based changes in items. We aim to analyze longitudinal disease progression based on MDS-UPRDS parts 2 and 3 item-level responses over time and as functions of Hoehn & Yahr (H&Y) stages 1 and 2 for subjects with early PD. The longitudinal item response theory (IRT) modeling is a novel statistical method addressing limitations in traditional linear regression approaches, such as ignoring varying item sensitivities and the sum score balancing out improvements and declines. We utilized a harmonized dataset consisting of six studies with 3573 subjects with early PD and 14,904 visits, and mean follow-up time of 2.5 years (±1.57). We applied both a unidimensional (each part separately) and multidimensional (both parts combined) longitudinal IRT models. We assessed the progression rates for both parts, anchored to baseline H&Y stages 1 and 2. Both the uni- and multidimensional longitudinal IRT models indicate significant worsening time effects in both parts 2 and 3. Baseline H&Y stage 2 was associated with significantly higher baseline severities, but slower progression rates in both parts, as compared with stage 1. Patients with baseline H&Y stage 1 demonstrated slower progression in part 2 severity compared to part 3, whereas patients with baseline H&Y stage 2 progressed faster in part 2 than part 3. The multidimensional model had a superior fit compared to the unidimensional models and it had excellent model performance.

摘要

运动障碍协会修订的帕金森病统一评定量表(MDS-UPDRS)第 2 部分和第 3 部分分别反映了患者报告的帕金森病(PD)功能影响和临床医生报告的运动体征严重程度。总评分是常见的临床结果,但可能掩盖了项目在时间上的重要变化。我们旨在分析基于 MDS-UPRDS 第 2 部分和第 3 部分项目水平反应的纵向疾病进展,以及随着时间的推移和 Hoehn 和 Yahr(H&Y)分期 1 和 2 的变化,用于早期 PD 患者。纵向项目反应理论(IRT)模型是一种新颖的统计方法,解决了传统线性回归方法的局限性,例如忽略了不同项目的敏感性以及总分平衡了改善和下降。我们利用了一个包含六个研究的协调数据集,其中有 3573 名早期 PD 患者和 14904 次就诊,平均随访时间为 2.5 年(±1.57)。我们应用了一维(每个部分单独)和多维(两个部分结合)纵向 IRT 模型。我们评估了两个部分的进展速度,以基线 H&Y 分期 1 和 2 为参照。一维和多维纵向 IRT 模型都表明,第 2 部分和第 3 部分的时间影响都有显著恶化。与分期 1 相比,基线 H&Y 分期 2 与更高的基线严重程度和更慢的进展速度相关。与第 3 部分相比,基线 H&Y 分期 1 的患者在第 2 部分严重程度的进展较慢,而基线 H&Y 分期 2 的患者在第 2 部分的进展快于第 3 部分。多维模型比一维模型具有更好的拟合度,且具有出色的模型性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c40/9574723/fc05350b268f/PSP4-11-1382-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c40/9574723/f2ba1834f6b3/PSP4-11-1382-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c40/9574723/fc05350b268f/PSP4-11-1382-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c40/9574723/f2ba1834f6b3/PSP4-11-1382-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c40/9574723/fc05350b268f/PSP4-11-1382-g001.jpg

相似文献

1
Application of longitudinal item response theory models to modeling Parkinson's disease progression.纵向项目反应理论模型在帕金森病进展建模中的应用。
CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1382-1392. doi: 10.1002/psp4.12853. Epub 2022 Aug 9.
2
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.同时使用运动障碍学会统一帕金森病评定量表第 2 部分和第 3 部分:将患者声音与临床医生评分相结合。
Mov Disord. 2023 Mar;38(3):453-463. doi: 10.1002/mds.29308. Epub 2023 Jan 9.
3
Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.MDS-UPDRS 是否能精确评估早期帕金森病的进展?帕金森病进展标志物倡议队列的研究结果。
J Neurol. 2019 Aug;266(8):1927-1936. doi: 10.1007/s00415-019-09348-3. Epub 2019 May 9.
4
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling.剖析帕金森病的领域:来自纵向项目反应理论建模的见解。
Mov Disord. 2022 Sep;37(9):1904-1914. doi: 10.1002/mds.29154. Epub 2022 Jul 16.
5
Novel Approach to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models.临床试验中运动障碍学会统一帕金森病评定量表监测的新方法:纵向项目反应理论模型
Mov Disord Clin Pract. 2021 Aug 3;8(7):1083-1091. doi: 10.1002/mdc3.13311. eCollection 2021 Oct.
6
The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.帕金森病症状起始侧与 MDS-UPDRS 量表第四部分(运动并发症)表现之间的关联。
J Neurol Sci. 2019 Jan 15;396:262-265. doi: 10.1016/j.jns.2018.12.002. Epub 2018 Dec 4.
7
Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine.解决运动障碍学会统一帕金森病评定量表中的缺失数据:远程医疗的影响。
Mov Disord. 2022 Aug;37(8):1749-1755. doi: 10.1002/mds.29129. Epub 2022 Jun 18.
8
Modeling a Composite Score in Parkinson's Disease Using Item Response Theory.使用项目反应理论对帕金森病综合评分进行建模。
AAPS J. 2017 May;19(3):837-845. doi: 10.1208/s12248-017-0058-8. Epub 2017 Feb 28.
9
Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real-world Unified Parkinson's Disease Rating Scale.使用真实世界统一帕金森病评定量表的项目反应理论评估预测帕金森病左旋多巴剂量需求的纵向变化。
CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):611-621. doi: 10.1002/psp4.12632. Epub 2021 May 3.
10
Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times.帕金森病的进展通过 Hoehn 和 Yahr 分期的阶段转移时间来评估。
Mov Disord. 2010 Apr 30;25(6):710-6. doi: 10.1002/mds.22875.

引用本文的文献

1
Sparse item testing of clinical scales in neurology trials to alleviate burden to patients.神经病学试验中临床量表的稀疏项目测试以减轻患者负担。
J Neurol. 2024 Oct;271(10):6847-6855. doi: 10.1007/s00415-024-12650-4. Epub 2024 Aug 30.
2
Tips and tricks in tremor treatment.震颤治疗的技巧和窍门。
J Neural Transm (Vienna). 2024 Oct;131(10):1229-1246. doi: 10.1007/s00702-024-02806-x. Epub 2024 Jul 24.
3
Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling.通过纵向项目反应理论建模评估替拉沃单抗在早期阿尔茨海默病中的疗效。

本文引用的文献

1
Novel Approach to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models.临床试验中运动障碍学会统一帕金森病评定量表监测的新方法:纵向项目反应理论模型
Mov Disord Clin Pract. 2021 Aug 3;8(7):1083-1091. doi: 10.1002/mdc3.13311. eCollection 2021 Oct.
2
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.别嘌醇升尿酸对早期帕金森病进展的影响:SURE-PD3 随机临床试验。
JAMA. 2021 Sep 14;326(10):926-939. doi: 10.1001/jama.2021.10207.
3
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update.
Alzheimers Dement (N Y). 2024 Jun 4;10(2):e12471. doi: 10.1002/trc2.12471. eCollection 2024 Apr-Jun.
4
Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson's Disease: A Retrospective Study by Different Expert Centers.在帕金森病中用专业康复治疗补充最佳护理:不同专家中心的一项回顾性研究
J Clin Med. 2024 May 20;13(10):2999. doi: 10.3390/jcm13102999.
5
Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS).罕见神经退行性疾病中包含参数不确定性的个体疾病进展预测:常染色体隐性痉挛性共济失调 Charlevoix Saguenay (ARSACS) 的实例。
AAPS J. 2024 Apr 30;26(3):57. doi: 10.1208/s12248-024-00925-7.
6
Role of dopamine agonists in Parkinson's disease therapy.多巴胺激动剂在帕金森病治疗中的作用。
J Neural Transm (Vienna). 2023 Jun;130(6):863-873. doi: 10.1007/s00702-023-02647-0. Epub 2023 May 11.
7
Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.同时使用运动障碍学会统一帕金森病评定量表第 2 部分和第 3 部分:将患者声音与临床医生评分相结合。
Mov Disord. 2023 Mar;38(3):453-463. doi: 10.1002/mds.29308. Epub 2023 Jan 9.
帕金森病临床试验药物治疗:2021 年更新。
J Parkinsons Dis. 2021;11(3):891-903. doi: 10.3233/JPD-219006.
4
Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models.通过纵向项目得分模型检测帕金森病症状的安慰剂和药物效应。
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):309-317. doi: 10.1002/psp4.12601.
5
Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real-world Unified Parkinson's Disease Rating Scale.使用真实世界统一帕金森病评定量表的项目反应理论评估预测帕金森病左旋多巴剂量需求的纵向变化。
CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):611-621. doi: 10.1002/psp4.12632. Epub 2021 May 3.
6
Modelling item scores of Unified Parkinson's Disease Rating Scale Part III for greater trial efficiency.建立统一帕金森病评定量表第三部分的项目评分模型以提高试验效率。
Br J Clin Pharmacol. 2021 Sep;87(9):3608-3618. doi: 10.1111/bcp.14777. Epub 2021 Mar 15.
7
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson's Disease.随机对照试验:聚焦超声丘脑底核切开术治疗帕金森病。
N Engl J Med. 2020 Dec 24;383(26):2501-2513. doi: 10.1056/NEJMoa2016311.
8
Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial.幽门螺杆菌根除治疗帕金森病:一项随机安慰剂对照试验。
Mov Disord. 2020 Dec;35(12):2250-2260. doi: 10.1002/mds.28248. Epub 2020 Sep 7.
9
Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results.癌症临床试验中健康相关生活质量的纵向分析:方法和结果解读。
Qual Life Res. 2021 Jan;30(1):91-103. doi: 10.1007/s11136-020-02605-3. Epub 2020 Aug 18.
10
Performance of longitudinal item response theory models in shortened or partial assessments.在缩短或部分评估中纵向项目反应理论模型的性能。
J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):461-471. doi: 10.1007/s10928-020-09697-x. Epub 2020 Jul 2.